Entering text into the input field will update the search result below

Tempest Therapeutics CEO Stephen Brady - Small Molecule Cancer Treatment

CEO Interviews profile picture
CEO Interviews


  • Tempest Therapeutics is a clinical-stage biotech developing small molecule therapy to treat cancer.
  • CEO Stephen Brady joined us to discuss clinical studies, partnering with Roche and how he thinks about licensing and M&A.
  • Allowing the immune system to do its job; biotech investing trends.

  • 1:40 - Steve left life as a banker and lawyer on his way to becoming Tempest's (NASDAQ:TPST) CEO.
  • 12:30 - Hematological malignancies, solid tumors and treating unmet needs.
  • 18:00 - Clinical studies and data updates.
  • 27:00 - Roche (OTCQX:RHHBY) partnership; licensing and M&A.
  • 38:00 - Biotech investing trends. Leveraging immune system with different opportunities.


Please note that transcription may not be perfect. We encourage you to listen to the video, embedded above, if you need any clarification.

Jason Robinson: Welcome to Seeking Alpha CEO interviews. Today I'm joined by Steve Brady, CEO of Tempest Therapeutics. Tempest is a clinical stage biotech company focusing on developing first in class small molecule therapeutics to treat cancer through mechanisms that directly kill tumors, tumor cells and activate tumor specific immunity.

Tempest trades on the Nasdaq under the ticker symbol TPST and Steve, welcome, and thanks for joining us. I really appreciate you jumping on.

Stephen Brady: Thank you, Jason. Appreciate you having us.

Jason Robinson: Of course, and just some background context for our viewers. I know Tempest went public early 2021 via the reverse merger with Melindo. I know you have an extensive background, a lot of experience in the biotech industry, with a number of different various roles eventually resulting in the CEO position.

So if you give me a little background and context on your background and kind of how you landed attempt, this would be fantastic.

Stephen Brady: Sure. So I actually started out as a corporate finance attorney while I was in grad school in New York and at Merck. I'm a Californian, came back to California after graduating from NYU, did the big firm Morrison and force their lawyer piece and then was recruited out to be an investment banker on one of the deals I was working on by

This article was written by

CEO Interviews profile picture
Quality leadership is a significant factor in successful companies. CEO Interviews brings you informed conversations with CEOs in the publicly traded markets. The show provides intimate and in-depth investing discussions with industry leaders across all sectors of the marketplace.

Recommended For You

Comments (1)

Great interview. Stock price really tanked though. None of the assets are priced in to current share price. Very thinly traded. I called the company and left a message for investor relations with live operator and said I am looking to heavily invest…no call back in past 3 weeks.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.